SPRO•benzinga•
UPDATE: Spero Restructuring Related To Cessation Of Commercialization Activities For Tebipenem Will Reduce Co.'s Workforce From 146 Full-Time Employees To ~35 Employees; Co. Will Incur $8M In Costs Related To Workforce Reduction
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 3, 2022 by benzinga